CpG Diagnostics

Ovarian Cancer Diagnosis Shouldn’t Be a Guess

Current tests cannot reliably distinguish between benign and malignant adnexal masses. This leaves women facing two risks: surgery when it isn’t needed or undertreatment when cancer is present — all while living with the anxiety of uncertainty.

LEARN ABOUT THIS ISSUE

Learn About Our Solution

The Case for Better Diagnostic Tools

Up to 20% of women will be diagnosed with an adnexal mass in their lifetime. As imaging and current tests cannot always tell the difference, many women undergo surgery for evaluation. Nearly 80% of these tumors are ultimately benign. The lack of accurate diagnostic tools leads to unnecessary and invasive procedures while cancers may be missed or undertreated.

Learn more

"Women with adnexal masses deserve better tools. Without a reliable test, many face uncertainty about whether surgery is needed and what type is best. This gap limits how confidently clinicians can guide care, highlighting the need for solutions that help ensure women receive the right surgery, performed with the right approach."

BODOUR SALHIA,PhD

FOUNDER

ADNEXAL MASS DISCOVERY

UNRELIABLE
DIAGNOSTICS

INSUFFICENT
INFORMATION

Delivering Certainty When It Matters Most

We're developing precision diagnostics matching medical need.

Learn More

We aim to empower physicians to accurately distinguish malignant from benign masses through a simple blood draw.

We aim to reduce unnecessary surgeries while ensuring high-risk patients receive timely specialist care.

We leverage AI-powered analysis trained on thousands of methylation patterns to deliver reliable results for all women.

Our Approach to Addressing The Diagnostic Crisis

Moving Beyond Protein
Markers to DNA Truth

Methylation Science meets Artificial Intelligence

For decades, we've relied on protein markers that weren't designed for the precision today's medicine demands. Our methylation-based approach reads the actual DNA changes that distinguish cancer from benign tissue—delivering the accuracy that both physicians and patients deserve.

From Discovery
to Clinical Impact

Rigorous Validation for Real-World Application

Through our multi-center clinical validation study across leading U.S. medical centers, we are analyzing thousands of methylation patterns across diverse patient populations to build diagnostics that work for all women and eliminate unnecessary surgeries.

Our Evidence is Growing

Our pivotal study, published in Clinical Cancer Research (2023), demonstrated that OvaPrint™ distinguishes high-grade serous ovarian carcinoma (HGSOC) - the most lethal ovarian cancer subtype - from benign adnexal masses with unprecedented specificity and sensitivity. Building on this foundation, OvaPrint™ has since been expanded to include other epithelial ovarian cancer subtypes.

This proof-of-concept laid the groundwork for our national clinical trial now underway, designed to rigorously validate OvaPrint across diverse ovarian cancer subtypes, patient populations, and clinical settings.

What We Are Developing